- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04137068
Sedentary Behavior, Cardiovascular Function, and Sleep (PACE)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
PRIMARY OBJECTIVES:
1. To test the hypothesis that two weeks of sedentary behavior will progressively impair vascular endothelial function.
2: To test the hypothesis that increasing sedentary behavior will decrease total sleep duration and sleep efficiency.
3: To test the hypothesis that two-weeks of sedentary behavior will progressively increase 24-h blood pressure and reduce nocturnal blood pressure dipping.
OUTLINE:
After a baseline period, participants will become more inactive and also come in for 4-h uninterrupted sitting visits. Cardiovascular, activity, and sleep measures will be taken throughout.
Tipo de estudio
Inscripción (Anticipado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Reclutamiento
- Oregon Institute of Occupational Health Sciences
-
Contacto:
- Saurabh Thosar, Dr.
- Número de teléfono: 503-494-2064
- Correo electrónico: thosar@ohsu.edu
-
Investigador principal:
- Saurabh Thosar, Dr.
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Ages 20-80y
- Lean and overweight (BMI 18.5-40 kg/m2)
- No acute, chronic, or debilitating medical conditions
- No prescription/non-prescription medications or drugs of abuse
- Limited weight training or intense exercise (swimming, CrossFit)
- Non-smoker
- Average level of daily physical activity (8,000-12,499 steps/day)
- Persons who fit all the above criteria and are suitable based on a medical history and health habits questionnaire, sleep profiling questionnaire, and electrocardiogram and clinical biochemical screening tests of blood and urine may be eligible to participate.
Exclusion Criteria:
- Persons with any acute, chronic, or debilitating medical condition except pre-hypertension and/or mild to moderate sleep apnea will be excluded.
- Persons with any symptoms of acute or active illness (e.g. fever, leukocytosis) will be excluded.
- Persons with a history of severe psychiatric illness or psychiatric disorders will be excluded.
- Persons with a history of regular night/or rotating shift work, or who have traveled more than three time zones during the one month prior to the study will be excluded.
- Pregnant persons, decisionally impaired adults, and prisoners will be excluded.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Otro: Sedentary to Active
Participants will visit the research laboratory for baseline measurements at visit 1 after wearing a pedometer for one week and maintaining their typical level of physical activity.
After the baseline visit, participants will reduce their step count by more than half for two weeks.
Participants will visit the laboratory once every week during the 2 week interventional period for a total of 3 visits.
|
Participants reduce their activity level to <5,000 steps/day and <50 % of baseline steps.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Endothelial Function
Periodo de tiempo: 3 weeks
|
Investigators will measure endothelial function as flow-mediated dilation at baseline, and each hour of the 3-hour sitting trials.
|
3 weeks
|
|
Oxidative stress
Periodo de tiempo: 3 weeks
|
Oxidative stress will be measured using malondialdehyde adducts (MDA) from Ethylenediaminetetraacetic acid (EDTA) plasma.
|
3 weeks
|
|
Endothelin-1
Periodo de tiempo: 3 weeks
|
Endothelin 1 (ET-1) will be measured from Ethylenediaminetetraacetic acid (EDTA) plasma.
|
3 weeks
|
|
Heart rate
Periodo de tiempo: 3 weeks
|
During the weekly trials, heart rate will be measured as beats per minute while participants are in a seated position during the prolonged sitting period.
|
3 weeks
|
|
Blood pressure
Periodo de tiempo: 3 weeks
|
During the weekly trials, blood pressure will be measured as systolic over diastolic in a seated position in the dominant arm
|
3 weeks
|
|
24-hour BP measurement
Periodo de tiempo: 3 weeks
|
Investigators will measure 24-hour ambulatory blood pressure monitoring (AMBP, Spacelabs, Inc) at baseline and for 24-h before each in-lab visit.
|
3 weeks
|
|
Sleep duration
Periodo de tiempo: 3 weeks
|
Sleep duration will be scored from the ActiGraph and correlated with the sleep and activity diary.
|
3 weeks
|
|
Sleep efficiency
Periodo de tiempo: 3 weeks
|
Sleep efficiency will be scored from the ActiGraph and correlated with the sleep and activity diary.
|
3 weeks
|
|
Activity
Periodo de tiempo: 3 weeks
|
Activity will be scored from the ActiGraph and correlated with the sleep and activity diary.
|
3 weeks
|
|
Activity Perception
Periodo de tiempo: 3 weeks
|
Activity perception will be measured before each prolonged sitting trial using an Activity Perception questionnaire (Perception of Current Activity Questionnaire).
The questionnaire has 7 questions with answers ranging from 1 to 5. The range of scores is from 7 to 35, with 7 suggesting a strong negative perception of current activity, and 35 suggesting a strong positive perception of current activity.
|
3 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Saurabh Thosar, Dr., Oregon Institute of Occupational Health Sciences
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- STUDY00020458
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .